Physician profile

Vicki E Smith

Pediatrics · Pittsfield, MA

NPI 1629060298

$745.56

in general payments reported to CMS, 2019-2025

10 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$32.98

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Ironshore Pharmaceuticals INC. $231.40 2019-2020
Glaxosmithkline, LLC. $137.72 2019-2020
Teva Pharmaceuticals USA, INC. $109.50 2019
Comsort, INC $100.00 2019
Merck Sharp & Dohme LLC $63.43 2019-2023 Gardasil 9, Vaxneuvance, Vaxelis
Sobi, INC $27.77 2019-2020
Phadia US INC. $23.85 2021
Cranial Technologies, INC $22.39 2021
Sanofi Pasteur INC. $15.23 2022
Pfizer INC. $14.27 2023

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Vicki E Smith

$745.56

in general payments reported 2019-2025

Years
2019-2023
Top company
Ironshore Pharmaceuticals INC.

https://glasscript.com/doctor/255475/vicki-e-smith

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.